Mesoblast enters MoU for US clinical trial for Revascor

Company News

by Rachael Jones

Biotech company Mesoblast (ASX:MSB) today announced that the International Center for Health Outcomes and Innovation Research have entered into a Memorandum of Understanding (MOU) for a clinical trial using Mesoblast’s product candidate Revascor (MPC-150-IM).

Revascor is for the reduction of gastrointestinal (GI) bleeding in end-stage heart failure patients implanted with a left ventricular assist device (LVAD).

Mesoblast is a global leader in cellular medicines for inflammatory diseases.

In a 30-patient pilot trial, Revascor showed a 70 per cent reduction in GI bleeding events.

Mesoblast plans to meet with the FDA in the upcoming quarter to discuss an approval pathway for Revascor under its existing Regenerative Medicine Advanced Therapy RMAT designation.

Shares in Mesoblast (ASX:MSB) closed -1.06 per cent lower to $1.40 yesterday. 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.